TY - JOUR
T1 - Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype
AU - Theriault, Rachel L.
AU - Litton, Jennifer K.
AU - Mittendorf, Elizabeth A.
AU - Chen, Huiqin
AU - Meric-Bernstam, Funda
AU - Chavez-MacGregor, Mariana
AU - Morrow, Phuong K.
AU - Woodward, Wendy A.
AU - Sahin, Aysegul
AU - Hortobagyi, Gabriel N.
AU - Gonzalez-Angulo, Ana M.
N1 - Funding Information:
A.M.G. is supported in part by an ASCO Career Development Award and grant NCI 1K23CA121994-01 . The M. D. Anderson Breast Cancer Management System and the Breast Tumor Bank are supported in part by the Nelly B. Connally Breast Cancer Research Fund.
PY - 2011/10
Y1 - 2011/10
N2 - The treatment of tumors ≤1 cm are difficult to treat as recurrence rates are difficult to assess. The purpose of this study was to assess recurrence by underlying triple receptor subtype and by age, both of which had significant impact on outcomes. Aim: This article evaluates the risk of recurrence for patients who have small node-negative breast cancer by age and tumor subtype. Methods: One thousand twelve patients with a T1a,bN0 breast cancer diagnosed between 1990 and 2002 who did not receive chemotherapy or trastuzumab were included. Patients and tumor characteristics were compared using the x 2 or Wilcoxon's rank sum tests. Survival outcomes were estimated with the Kaplan-Meier method and compared using the log-rank statistic. Cox proportional hazards models were used to determine association of breast cancer subtypes and age at diagnosis with other covariates. Results: Median age was 51.5 years. There were 771 hormone receptor (HR)-positive, 98 HER2-positive, and 143 triple-negative breast cancers (TNBC). Six hundred ninety-three patients were > 50 years, and 33 patients were≤35 years. For 5-year survival estimates, there were 118 deaths and overall survival was 94.6% (95% confidence interval [CI]-93.2%, 96.1%). After adjusting for breast cancer subtype and other tumor characteristics, patients≤35 had 2.51 (95% CI = 1.21-5.22) times greater risk of worse recurrence-free survival (RFS), and 2.60 (95% CI = 1.05-6.46) times greater risk of worse distant RFS (DRFS) compared to patients>50 years old. Compared to patients with HR-positive disease, patients with HER2-positive breast cancer had 4.98 (95% CI = 2.91-8.53) times the risk of worse RFS and 4.70 (95% CI = 2.51-8.79) times greater risk of worse DRFS, and patients with TNBC had 2.71 (95% CI = 1.59-4.59) times greater risk of worse RFS and 2.08 (95% CI = 1.04-4.17) times greater risk of worse DRFS. Conclusions: In this cohort, patients with T1a,bN0 breast cancer, young age and breast cancer subtype were significantly associated with RFS and DRFS.
AB - The treatment of tumors ≤1 cm are difficult to treat as recurrence rates are difficult to assess. The purpose of this study was to assess recurrence by underlying triple receptor subtype and by age, both of which had significant impact on outcomes. Aim: This article evaluates the risk of recurrence for patients who have small node-negative breast cancer by age and tumor subtype. Methods: One thousand twelve patients with a T1a,bN0 breast cancer diagnosed between 1990 and 2002 who did not receive chemotherapy or trastuzumab were included. Patients and tumor characteristics were compared using the x 2 or Wilcoxon's rank sum tests. Survival outcomes were estimated with the Kaplan-Meier method and compared using the log-rank statistic. Cox proportional hazards models were used to determine association of breast cancer subtypes and age at diagnosis with other covariates. Results: Median age was 51.5 years. There were 771 hormone receptor (HR)-positive, 98 HER2-positive, and 143 triple-negative breast cancers (TNBC). Six hundred ninety-three patients were > 50 years, and 33 patients were≤35 years. For 5-year survival estimates, there were 118 deaths and overall survival was 94.6% (95% confidence interval [CI]-93.2%, 96.1%). After adjusting for breast cancer subtype and other tumor characteristics, patients≤35 had 2.51 (95% CI = 1.21-5.22) times greater risk of worse recurrence-free survival (RFS), and 2.60 (95% CI = 1.05-6.46) times greater risk of worse distant RFS (DRFS) compared to patients>50 years old. Compared to patients with HR-positive disease, patients with HER2-positive breast cancer had 4.98 (95% CI = 2.91-8.53) times the risk of worse RFS and 4.70 (95% CI = 2.51-8.79) times greater risk of worse DRFS, and patients with TNBC had 2.71 (95% CI = 1.59-4.59) times greater risk of worse RFS and 2.08 (95% CI = 1.04-4.17) times greater risk of worse DRFS. Conclusions: In this cohort, patients with T1a,bN0 breast cancer, young age and breast cancer subtype were significantly associated with RFS and DRFS.
KW - Distant recurrence-free survival
KW - HER2
KW - Hormone receptor
KW - Recurrence-free survival
KW - Triple-negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=84855746053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855746053&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2011.05.002
DO - 10.1016/j.clbc.2011.05.002
M3 - Article
C2 - 21764391
AN - SCOPUS:84855746053
SN - 1526-8209
VL - 11
SP - 325
EP - 331
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 5
ER -